Active Pharmaceutical Ingredient (API) Market

Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), by product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD) - Global Forecast to 2025

Report Code: PH 1262 Sep, 2020, by marketsandmarkets.com

[337 Pages Report] The global active pharmaceutical ingredients market size is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period. Market growth is driven mainly by factors such as rising drug R&D, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. On the other hand, unfavorable drug price control policies across various countries and high manufacturing costs are expected to restrain the growth of this market.

Attractive Opportunities in the Active pharmaceutical ingredients Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the active pharmaceutical ingredients market

With the WHO declaring the COVID-19 outbreak a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments that target the infection. In just a few weeks, scientists found a list of molecules that target COVID-19. Currently, around 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. In this list, there are four promising drugs (Remdesivir, Chloroquine & Hydroxychloroquine, Lopinavir & Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a) that have been repurposed for use against COVID-19. On March 24, 2020, the WHO announced that it had initiated a global mega trial of the four most promising drugs against COVID-19. Countries are in a global race to develop and mass-produce an efficient vaccine to fight COVID-19. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale. According to the WHO, as of June 2020, there were over 140 vaccines in various stages of development. Of these, 13 are now in the human clinical trial stage, while others remain at the very early stages of preclinical testing. Increase in funding and research for development of pharmaceutical products will drive growth for the market. However, coronavirus outbreak has disrupted business and economic activities globally.in the first quarter of 2020 It is expected to have a short-term impact on the active pharmaceutical ingredients market to a certain extent. 

Global Active pharmaceutical ingredients Market Dynamics

DRIVER: Increasing incidence of chronic diseases

Over the last few decades, the incidence of chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased significantly in major regions across the globe. This can be attributed to the rising geriatric population across the globe (by 2050, more than 20% of the global population is expected to be aged over 65 years), changing lifestyles, and dietary changes as a result of rapid urbanization. According to the International Diabetes Federation, in 2019, 463 million people worldwide were diagnosed with diabetes. Moreover, the number of new cancer cases per year is expected to rise to 23.6 million by 2030. Apart from cancer, a number of other diseases have shown increasing prevalence rates. 

RESTRAINT:  High manufacturing costs

The high manufacturing cost of APIs is one of the major challenges faced by market players. Manufacturers often have to make costly investments for improvements in their manufacturing facilities to ensure compliance with standards such as the cGMP. This includes the renovation of production facilities, inculcating familiarity with qualification requirements and processes, and building a dossier of product efficacy and safety tests that meet the requirements of regulatory authorities. Furthermore, the costs of obtaining regulatory approvals are relatively higher for firms with small volumes. The chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials, which further adds to API manufacturing costs.

OPPORTUNITY: Emerging biosimilars market

The rising incidence of various diseases, the increasing number of off-patent biologic drugs, positive outcomes in ongoing clinical trials for biosimilars, and the rising demand for biosimilars in different therapeutic applications (such as rheumatoid arthritis and blood disorders) are the major factors driving the growth of the biosimilars market. Biosimilars are generic versions of patented biologic drugs; hence, they do not need to comply with the stringent requirements of various regulatory authorities (making them cost-effective as compared to patented biologics). The expiration of patents and other intellectual property rights for originator biologics over the next decade is expected to open up opportunities for biosimilars to enter the market.

The innovative APIs segment dominated the active pharmaceutical ingredients market in 2019.

Based on type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment accounted for the largest share of the global active pharmaceutical ingredients market in 2019. Increased FDA approvals for new molecular entities, high price of innovative APIs as compared to the generic drugs, increased focus on R&D by the innovator API companies are the factors contributing towards the growth of the innovative APIs segment. 

The oncology segment will witness the highest growth during the forecast period

Based on application, the active pharmaceutical ingredients market is segmented into communicable diseases, oncology, cardiovascular diseases, diabetes, pain management, chronic respiratory diseases, and other therapeutic application. neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the oncology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven by the increasing demand for highly potent APIs (HPAPIs) for the treatment of cancer. 

Active Pharmaceutical Ingredients Market By Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for active pharmaceutical ingredients in 2019.

Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and Rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs

Key Market Players

Key players in the active pharmaceutical ingredients market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).

Scope of the report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

type, type of manufacturer, type of synthesis, type of drug, application and region

Geographies covered

North America, Europe, Asia, and Rest of the World

Companies covered

Pfizer, Inc. (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Cipla, Inc. (India), Mylan N.V. (US), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), API Pharma Tech (India), BDR Pharmaceuticals Internationals Pvt. Ltd. (India), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India)

This report categorizes the active pharmaceutical ingredients market into the following segments and subsegments:

APIs Market, by Type

  • Innovative APIs
  • Generic APIS

APIs Market, by Type of Manufacturer

  • Captive Manufacturers
  • Merchant Manufacturers
    • Merchant Manufacturers Market, by Type
    • Innovative Merchant API Manufacturers
    • Generic Merchant API Manufacturers
    • Merchant Manufacturers Market, by Type of Synthesis
    • Synthetic APIs
    • Biotech APIs

APIs market, by Type of Synthesis

  • Synthetic APIs Market
    • Synthetic APIs Market, by Type
    • Innovative Synthetic APIs
    • Generic Synthetic APIs
  • Biotech APIs Market
    • Biotech APIs Market, by Type
    • Innovative Biotech APIs
    • Biosimilars
    • Biotech APIs Market, by Product
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Fusion Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
    • Biotech APIs Market, by Expression System
    • Mammalian Expression Systems
    • Microbial Expression Systems
    • Yeast Expression Systems
    • Insect Expression Systems
    • Other Expression Systems (Plant expression systems)

APIs Market, by Type of Drug

  • Prescription Drugs
  • Over-the-counter Drugs

APIs Market, by Therapeutic Application

  • Communicable Diseases
  • Oncology
  • Diabetes
  • Cardiovascular Disease
  • Pain management
  • Respiratory Diseases
  • Other Therapeutic Applications (Orthopedics, Urology and Nephrology, Ophthalmology, Pulmonology, Women’s Health, and Gastroenterology)

API Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Hungary
    • Rest of Europe (RoE)
  • Asia
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia (RoA)
  • Rest of the World (RoW)
  • Israel
  • Other countries 

Recent Developments

  • In 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.
  • In 2020, Novartis (Switzerland) acquired Aspen’s Japanese operations to strengthen its position in the global generics and off-patent medicines market. Novartis also entered into a manufacturing and supply agreement with Aspen.
  • In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio. 

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS 
 
1 INTRODUCTION (Page No. - 51)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                 FIGURE 1 MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 55)
    2.1 RESEARCH DATA
        FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY SOURCES
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY SOURCES
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                            FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
    2.2 MARKET SIZE ESTIMATION
        FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
        FIGURE 5 MARKET SIZE ESTIMATION: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 64)
  FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020 VS. 2025 (USD BILLION)
  FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2020 VS. 2025 (USD BILLION)
  FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020 VS. 2025 (USD BILLION)
  FIGURE 10 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT,  2020 VS. 2025 (USD BILLION)
  FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020 VS. 2025 (USD BILLION)
  FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 68

4 PREMIUM INSIGHTS (Page No. - 69)
  4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW
      FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE THE KEY FACTORS DRIVING MARKET GROWTH
  4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE & TYPE OF MANUFACTURER (2019
      FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
  4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
      FIGURE 15 CHINA TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 72)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of chronic diseases
                    5.2.1.2 Technological advancements in API manufacturing
                    5.2.1.3 Growing importance of generics
                            TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2020
                    5.2.1.4 Increasing uptake of biopharmaceuticals
                            TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN THE US IN 2019
                    5.2.1.5 Growing adoption of AI-based tools for drug discovery
                    5.2.1.6 Adoption of organ-on-chip models in drug development
                    5.2.1.7 Focus on precision medicine
                    5.2.1.8 Investments in real-world evidence by pharmaceutical companies
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable drug price control policies
                    5.2.2.2 High manufacturing costs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging biosimilars market
                            TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL IN THE US (2019-2020)
                    5.2.3.2 Highly potent active pharmaceutical ingredients
                    5.2.3.3 Emerging markets
                    5.2.3.4 Emerging technologies
           5.2.4 CHALLENGES
                    5.2.4.1 Increasing penetration of counterfeit drugs
    5.3 IMPACT OF COVID-19 ON THE MARKET
        TABLE 4 INDICATIVE LIST OF COVID-19 THERAPEUTIC DRUGS IN  THE PIPELINE (CLINICAL)
           5.3.1 COVID-19 DRUG R&D: KEY DEVELOPMENTS
           5.3.2 COVID-19 DRUG R&D: VACCINE PRODUCTION SCENARIO, BY COUNTRY
    5.4 VALUE CHAIN ANALYSIS
        FIGURE 16 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
    5.5 SUPPLY CHAIN ANALYSIS
        FIGURE 17 DIRECT DISTRIBUTION-STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.6 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET
        FIGURE 18 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (Page No. - 89)
    6.1 INTRODUCTION
        TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
           6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET GROWTH
                 TABLE 6 INDICATIVE LIST OF BIOLOGICAL PRODUCTS THAT GAINED US FDA APPROVAL IN 2019
                 TABLE 7 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2020
                 TABLE 8 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
                 TABLE 9 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 10 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 11 ASIA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
    6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
           6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH
                 TABLE 12 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
                 TABLE 13 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 14 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 15 ASIA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
 
7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER (Page No. - 96)
    7.1 INTRODUCTION
        TABLE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    7.2 CAPTIVE API MANUFACTURERS
           7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY ARE THE KEY FACTORS SUPPORTING MARKET GROWTH
                 TABLE 17 CAPTIVE API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
                 TABLE 18 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 19 EUROPE: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                 TABLE 20 ASIA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
    7.3 MERCHANT API MANUFACTURERS
        TABLE 21 MERCHANT API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
        TABLE 22 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
        TABLE 23 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
        TABLE 24 ASIA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
           7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE
                 TABLE 25 MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                    7.3.1.1 Innovative API manufacturers
                               7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain the market growth
                                         TABLE 26 INNOVATIVE API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
                                         TABLE 27 NORTH AMERICA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 28 EUROPE: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 29 ASIA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                    7.3.1.2 Generic API manufacturers
                               7.3.1.2.1 Low manufacturing cost of generics will drive the growth of this segment
                                         TABLE 30 GENERIC API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
                                         TABLE 31 NORTH AMERICA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 32 EUROPE: GENERIC API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 33 ASIA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
           7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
                 TABLE 34 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 2018-2025 (USD BILLION)
                    7.3.2.1 Synthetic API manufacturers
                               7.3.2.1.1 Need for specialized manufacturing capabilities is driving the growth of this segment
                                         TABLE 35 SYNTHETIC API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
                                         TABLE 36 NORTH AMERICA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 37 EUROPE: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 38 ASIA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                    7.3.2.2 Biotech API manufacturers
                               7.3.2.2.1 Complexity of manufacturing biotech APIs has increased the focus on partnerships between companies and CMOs
                                         TABLE 39 BIOTECH API MANUFACTURERS MARKET, BY REGION,  2018-2025 (USD BILLION)
                                         TABLE 40 NORTH AMERICA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 41 EUROPE: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 42 ASIA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (Page No. - 110)
    8.1 INTRODUCTION
        TABLE 43 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
        TABLE 44 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
        TABLE 45 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
        TABLE 46 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
        TABLE 47 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
           8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
                 TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                    8.2.1.1 Innovative synthetic APIs
                               8.2.1.1.1 High value of innovative APIs to drive the growth of this segment
                                         TABLE 49 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 50 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 51 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 52 ASIA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.2.1.2 Generic synthetic APIs
                               8.2.1.2.1 Initiatives to promote the penetration of generics will drive the growth of this segment
                                         TABLE 53 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 54 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 55 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 56 ASIA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
        TABLE 57 TOP SELLING BIOLOGICS (2018
        TABLE 58 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
        TABLE 59 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
        TABLE 60 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
        TABLE 61 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
           8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
                 TABLE 62 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                    8.3.1.1 Innovative biotech APIs
                               8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the growth of this segment
                                         TABLE 63 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 64 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 65 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 66 ASIA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.1.2 Generic biotech APIs
                               8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment
                                         TABLE 67 INDICATIVE LIST OF BIOSIMILARS THAT GAINED THE US FDA APPROVAL  IN 2019 124
                                         TABLE 68 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 69 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 70 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 71 ASIA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
           8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
                 TABLE 72 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 2018-2025 (USD BILLION)
                    8.3.2.1 Monoclonal antibodies
                               8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment
                                         TABLE 73 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2019
                                         TABLE 74 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 75 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 76 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 77 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.2 Hormones & growth factors
                               8.3.2.2.1 The growing incidence of hormonal disorders will drive market growth
                                         TABLE 78 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 79 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 80 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 81 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.3 Cytokines
                               8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment
                                         TABLE 82 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 83 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 84 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 85 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.4 Fusion proteins
                               8.3.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive the growth of this segment
                                         TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 89 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.5 Recombinant vaccines
                               8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development-a positive indicator of growth
                                         TABLE 90 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 91 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 92 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 93 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.6 Therapeutic enzymes
                               8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management will drive the growth of this segment
                                         TABLE 94 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 95 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 96 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 97 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.2.7 Blood factors
                               8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment
                                         TABLE 98 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 99 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 100 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 101 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
           8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
                 TABLE 102 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                    8.3.3.1 Mammalian expression systems
                               8.3.3.1.1 Their ability to carry post-translational modifications will drive the market for these systems
                                         TABLE 103 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 104 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 
                                         TABLE 105 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 106 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                    8.3.3.2 Microbial expression systems
                               8.3.3.2.1 These systems provide high expression levels of proteins, which supports their use
                                         TABLE 107 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 108 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 109 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                                         TABLE 110 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                    8.3.3.3 Yeast expression systems
                               8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand
                                         TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 114 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.3.4 Insect expression systems
                               8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand
                                         TABLE 115 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
                                         TABLE 116 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 117 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                                         TABLE 118 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                    8.3.3.5 Other expression systems
                            TABLE 119 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
                            TABLE 120 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY,  2018-2025 (USD BILLION)
                            TABLE 121 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
                            TABLE 122 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (Page No. - 148)
    9.1 INTRODUCTION
        TABLE 123 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,  2018-2025 (USD BILLION)
    9.2 PRESCRIPTION DRUGS
           9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET
                 TABLE 124 PRESCRIPTION DRUGS MARKET, BY REGION, 2018-2025 (USD BILLION)
                 TABLE 125 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                 TABLE 126 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                 TABLE 127 ASIA: PRESCRIPTION DRUGS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
    9.3 OVER-THE-COUNTER DRUGS
           9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
                 TABLE 128 OVER-THE-COUNTER DRUGS MARKET, BY REGION,  2018-2025 (USD BILLION)
                 TABLE 129 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
                 TABLE 130 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
                 TABLE 131 ASIA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY,  2018-2025 (USD BILLION)
    9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY
           9.4.1 LOW-TO-MODERATE-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
                    9.4.1.1 Higher safety, good warning properties, and lack of genic effects characterize low-to-moderate-potency APIs
           9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS
                    9.4.2.1 Most drugs under development fall into this category
                            TABLE 132 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,  2018-2025 (USD BILLION)

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (Page No. - 155)
     10.1 INTRODUCTION
          TABLE 133 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
     10.2 COMMUNICABLE DISEASES
           10.2.1 INCREASING GLOBAL INCIDENCE OF COMMUNICABLE DISEASES TO DRIVE MARKET GROWTH
                  TABLE 134 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2018-2025 (USD BILLION)
                  TABLE 135 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 136 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 137 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
     10.3 ONCOLOGY
           10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT THE GROWTH OF THIS SEGMENT
                  TABLE 138 INDICATIVE LIST OF THE US FDA-APPROVED DRUGS FOR ONCOLOGY (2018
                  TABLE 139 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,  BY REGION, 2018-2025 (USD BILLION)
                  TABLE 140 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 141 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 142 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,  BY COUNTRY, 2018-2025 (USD BILLION)
     10.4 DIABETES
           10.4.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT
                  TABLE 143 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,  BY REGION, 2018-2025 (USD BILLION)
                  TABLE 144 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 145 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 146 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,  BY COUNTRY, 2018-2025 (USD BILLION)
     10.5 CARDIOVASCULAR DISEASES
           10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER
                  TABLE 147 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2025 (USD BILLION)
                  TABLE 148 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 149 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 150 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
     10.6 PAIN MANAGEMENT
           10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET
                  TABLE 151 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2018-2025 (USD BILLION)
                  TABLE 152 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 153 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 154 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
     10.7 RESPIRATORY DISEASES
           10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT
                  TABLE 155 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018-2025 (USD BILLION)
                  TABLE 156 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 157 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
                  TABLE 158 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
     10.8 OTHER THERAPEUTIC APPLICATIONS
          TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2018-2025 (USD BILLION)
          TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 162 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (Page No. - 171)
     11.1 INTRODUCTION
          TABLE 163 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,  2018-2025 (USD BILLION)
     11.2 NORTH AMERICA
          FIGURE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
          TABLE 164 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
          TABLE 166 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
          TABLE 167 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 168 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 169 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 170 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 171 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 172 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
          TABLE 173 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
          TABLE 174 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
          TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
          TABLE 176 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.2.1 US
                     11.2.1.1 The US is the largest market for active pharmaceutical ingredients in North America
                              TABLE 177 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 178 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 179 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 180 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 181 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE  OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 182 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 183 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 184 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 185 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 186 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 187 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,  2018-2025 (USD BILLION)
                              TABLE 188 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.2.2 CANADA
                     11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada
                              TABLE 189 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 190 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 191 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 192 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 193 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 194 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 195 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 196 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 197 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 198 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 199 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 200 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
     11.3 EUROPE
          TABLE 201 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 202 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 203 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
          TABLE 204 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 205 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 206 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 207 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 208 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
          TABLE 209 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
          TABLE 210 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
          TABLE 211 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
          TABLE 212 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
          TABLE 213 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.1 GERMANY
                     11.3.1.1 Germany dominates the European active pharmaceutical ingredients market
                              TABLE 214 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 215 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 216 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 217 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 218 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 219 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 220 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 221 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 222 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 223 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 224 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 225 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.2 FRANCE
                     11.3.2.1 An increase in annual pharmaceutical industry turnover will support market growth in France
                              TABLE 226 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 227 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 228 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 229 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 230 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 231 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 232 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 233 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 234 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 235 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 236 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.3 UK
                     11.3.3.1 Rising government investments will drive the growth of the UK market
                              TABLE 238 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 239 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 240 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 241 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 242 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 243 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 244 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 245 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 246 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 248 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 249 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.4 ITALY
                     11.3.4.1 Growing investment in API production will support market growth
                              TABLE 250 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 251 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 252 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 253 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 254 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 255 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 256 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 257 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 259 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 260 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.5 SPAIN
                     11.3.5.1 The Spanish market has been typically dominated by branded drugs
                              TABLE 262 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 263 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 264 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 265 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 266 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 267 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 270 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 273 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.6 HUNGARY
                     11.3.6.1 Rising incidence of chronic diseases will contribute to market growth
                              TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 275 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 276 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 277 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 278 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 279 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 280 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 281 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 282 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 283 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 284 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 285 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.3.7 REST OF EUROPE
                  TABLE 286 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                  TABLE 287 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                  TABLE 288 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                  TABLE 289 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 290 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 291 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 292 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 293 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                  TABLE 294 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                  TABLE 295 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                  TABLE 296 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,  2018-2025 (USD BILLION)
                  TABLE 297 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
     11.4 ASIA
          FIGURE 20 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
          TABLE 298 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 299 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 300 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
          TABLE 301 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 302 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 303 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 304 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 305 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
          TABLE 306 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
          TABLE 307 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
          TABLE 308 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
          TABLE 309 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,  2018-2025 (USD BILLION)
          TABLE 310 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.4.1 JAPAN
                     11.4.1.1 Japan dominates the Asian market for APIs
                              TABLE 311 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 312 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 313 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 314 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 315 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 316 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 317 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 318 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 319 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 320 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 321 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025(USD BILLION)
                              TABLE 322 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.4.2 CHINA
                     11.4.2.1 Government policies to increase medicine access and affordability will support market growth
                              TABLE 323 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 324 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 325 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 326 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 327 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 328 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 329 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 330 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 331 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 332 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 333 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 334 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.4.3 INDIA
                     11.4.3.1 India is a leading producer of generics
                              TABLE 335 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 336 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 337 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 338 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 339 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 340 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 341 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 342 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 343 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 344 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 345 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 346 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.4.4 SOUTH KOREA
                     11.4.4.1 Rising annual drug exports are likely to drive market growth
                              TABLE 347 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 348 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 349 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 350 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 351 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 352 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 353 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 354 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 355 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 356 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 357 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 358 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.4.5 REST OF ASIA
                  TABLE 359 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                  TABLE 360 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                  TABLE 361 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                  TABLE 362 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 363 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 364 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 365 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 366 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                  TABLE 367 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                  TABLE 368 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                  TABLE 369 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,  2018-2025 (USD BILLION)
                  TABLE 370 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
     11.5 REST OF THE WORLD
          TABLE 371 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
          TABLE 372 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 373 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
          TABLE 374 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
          TABLE 375 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 376 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
          TABLE 377 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
          TABLE 378 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
          TABLE 379 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
          TABLE 380 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
          TABLE 381 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
          TABLE 382 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
          TABLE 383 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.5.1 ISRAEL
                     11.5.1.1 Financial support by the government will drive market growth
                              TABLE 384 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 385 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                              TABLE 386 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2018-2025 (USD BILLION)
                              TABLE 387 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 388 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                              TABLE 389 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 390 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                              TABLE 391 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT, 2018-2025 (USD BILLION)
                              TABLE 392 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                              TABLE 393 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                              TABLE 394 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
                              TABLE 395 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
           11.5.2 OTHER COUNTRIES
                  TABLE 396 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 397 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
                  TABLE 398 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 399 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 400 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
                  TABLE 401 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 402 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
                  TABLE 403 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
                  TABLE 404 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
                  TABLE 405 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF DRUG, 2018-2025 (USD BILLION)
                  TABLE 406 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY POTENCY, 2018-2025 (USD BILLION)
                  TABLE 407 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 266)
     12.1 OVERVIEW
     12.2 MARKET EVALUATION FRAMEWORK
          TABLE 408 GROWTH STRATEGY MATRIX: EXPANSIONS AND COLLABORATIONS ARE THE WIDELY ADOPTED GROWTH STRATEGIES BY MARKET PLAYERS
     12.3 COMPETITIVE SITUATION AND TRENDS
          TABLE 409 PRODUCT LAUNCHES, JANUARY 2017?AUGUST 2020
          TABLE 410 EXPANSIONS, JANUARY 2017?AUGUST 2020
          TABLE 411 ACQUISITIONS, JANUARY 2017?AUGUST 2020
          TABLE 412 AGREEMENTS, COLLABORATIONS, ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2017?AUGUST 2020

13 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 270)
     13.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
     13.2 COMPANY EVALUATION MATRIX
           13.2.1 STARS
           13.2.2 EMERGING LEADERS
           13.2.3 PERVASIVE PLAYERS
           13.2.4 EMERGING COMPANIES
                  FIGURE 21 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - OVERALL MARKET
     13.3 COMPETITIVE LEADERSHIP MAPPING - START-UPS/SMES
           13.3.1 PROGRESSIVE COMPANIES
           13.3.2 STARTING BLOCKS
           13.3.3 RESPONSIVE COMPANIES
           13.3.4 DYNAMIC COMPANIES
                  FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - START-UPS/SMES
     13.4 MARKET PLAYER RANKING
                  FIGURE 23 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2019
     13.5 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View
           13.5.1 PFIZER, INC.
                  FIGURE 24 PFIZER, INC.: COMPANY SNAPSHOT (2019
           13.5.2 NOVARTIS AG
                  FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT (2019
           13.5.3 SANOFI
                  FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019
           13.5.4 BOEHRINGER INGELHEIM
                  FIGURE 27 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019
           13.5.5 BRISTOL-MYERS SQUIBB
                  FIGURE 28 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2019
           13.5.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                  FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019
           13.5.7 ELI LILLY AND COMPANY
                  FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019
           13.5.8 GLAXOSMITHKLINE PLC
                  FIGURE 31 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019
           13.5.9 MERCK & CO., INC.
                   FIGURE 32 MERCK & CO., INC.: COMPANY SNAPSHOT (2019
           13.5.10 MYLAN N.V.
                   FIGURE 33 MYLAN N.V.: COMPANY SNAPSHOT (2019
           13.5.11 ABBVIE INC.
                   FIGURE 34 ABBVIE INC.: COMPANY SNAPSHOT (2019
           13.5.12 F. HOFFMANN-LA ROCHE LTD.
                   FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019
           13.5.13 ASTRAZENECA
                   FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2019
           13.5.14 DR. REDDY'S LABORATORIES LTD.
                   FIGURE 37 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2019
           13.5.15 SUN PHARMACEUTICAL INDUSTRIES LTD.
                   FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019
           13.5.16 CIPLA, INC.
                   FIGURE 39 CIPLA, INC.: COMPANY SNAPSHOT (2019
           13.5.17 API PHARMA TECH
           13.5.18 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
           13.5.19 SREEPATHI PHARMACEUTICALS LIMITED
           13.5.20 SHILPA MEDICARE LIMITED

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 330)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS
     14.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the active pharmaceutical ingredients market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the active pharmaceutical ingredients market. The secondary sources used for this study include Active Pharmaceutical Ingredients Committee (APIC), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), International Pharmaceutical, Congress Advisory Association (IPCAA), European Generic and Biosimilar Medicines Association (EGBMA) and World Health Organization (WHO). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. 

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Active Pharmaceutical Ingredients Market Size

To know about the assumptions considered for the study, download the pdf brochure

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2019, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the active pharmaceutical ingredients market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the active pharmaceutical ingredients business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global active pharmaceutical ingredients market based on the type, type of manufacturer, type of synthesis, type of drug, application and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall active pharmaceutical ingredients market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia, and Rest of the World
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the active pharmaceutical ingredients market. 

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
COVID-19

Get in-depth analysis of the COVID-19 impact on the Active Pharmaceutical Ingredient (API) Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Active Pharmaceutical Ingredient (API) Market

Request For Special Pricing
Report Code
PH 1262
Published ON
Sep, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Active Pharmaceutical Ingredient (API) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home